JB pharma strengthens its position in gastroenterology with launch of RANRAFT

Published On 2022-11-08 12:30 GMT | Update On 2022-12-08 09:16 GMT

Gastroesophageal reflux disease (GERD), affects up to 1 in 5 Indian patients, causes heartburn, acid reflux and impacts the quality of life. It is worsened with the consumption of certain non-vegetarian food, spices, tobacco consumption etc.

Hence, in this endeavour, JB Pharma, makers of the popular drug Rantac strengthens its presence in the area of gastroenterology, by launching a unique formulation called RANRAFT to provide quick relief by neutralizing acid and preventing acid reflux.

For more details, check out the link given below:

JB Pharma Strengthens Its Position In Gastroenterology With Launch Of RANRAFT

Full View

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Roshni Dhar

Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

JB pharma strengthens its position in gastroenterology with launch of RANRAFT

Similar News